Company Valuation: Xcell Therapeutics Inc.

Data adjusted to current consolidation scope
Fiscal Period: December 2024 2025
Market Cap 1 44,384 28,726
Change - -35.28%
Enterprise Value (EV) 1 41,283 27,307
Change - -33.86%
P/E -4.26x -1.77x
PBR 4.87x 4.02x
PEG 0.47x 1.06x
Capitalization / Revenue 22.9x 14.7x
EV / Revenue 21.3x 14x
EV / EBITDA -5.38x -2.99x
EV / EBIT -4.42x -2.52x
EV / FCF -8.13x -4.03x
FCF Yield -12.3% -24.8%
Dividend per Share 2 - -
Rate of return - -
EPS 2 -954 -938
Distribution rate - -
Net sales 1 1,934 1,949
EBITDA 1 -7,677 -9,148
EBIT 1 -9,330 -10,852
Net income 1 -9,543 -10,927
Net Debt 1 -3,100 -1,419
Reference price 2 4,065.00 1,661.00
Nbr of stocks (in thousands) 10,918 17,294
Announcement Date 3/20/25 3/19/26
1KRW in Million2KRW
Estimates


P/E (Y) EV / Sales (Y) EV / EBITDA (Y) Dividend Yield (Y) Capi.($)
- - - - 12.75M
32.45x11.78x23.93x0.61% 1,019B
28.48x6.32x17.74x2.09% 617B
33.26x7.78x16.08x2.64% 464B
104.98x5.87x24.89x2.36% 356B
18.81x4.58x11.36x2.9% 333B
19.83x5.17x12.78x3.09% 267B
20.02x4.17x11.86x2.13% 244B
25.46x6.66x11.86x2.5% 218B
-43.78x6.39x24.97x2.27% 179B
Average 26.61x 6.52x 17.28x 2.29% 369.72B
Weighted average by Cap. 31.80x 7.61x 18.61x 1.96%

Y-o-Y evolution of P/E

Historical PBR trend

Evolution Enterprise Value / Sales

Change in Enterprise Value/EBITDA


  1. Stock Market
  2. Stocks
  3. A373110 Stock
  4. Valuation Xcell Therapeutics Inc.